Aerovate Therapeutics, Inc.
AVTE
$2.75
$0.072.61%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -69.63M | -84.61M | -87.94M | -82.19M | -75.52M |
| Total Depreciation and Amortization | 282.00K | 302.00K | 109.00K | 103.00K | 96.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.32M | 10.47M | 11.36M | 10.58M | 8.85M |
| Change in Net Operating Assets | -11.17M | -1.11M | 1.96M | 2.48M | 9.80M |
| Cash from Operations | -71.20M | -74.95M | -74.52M | -69.03M | -56.78M |
| Capital Expenditure | -- | -64.00K | -96.00K | -126.00K | -142.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 56.03M | 48.61M | 19.45M | 5.46M | 12.02M |
| Cash from Investing | 56.03M | 48.55M | 19.35M | 5.33M | 11.88M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 25.73M | 25.64M | 25.72M | 46.71M | 46.23M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -307.00K | -307.00K | -382.00K | -467.00K | -234.00K |
| Cash from Financing | 25.43M | 25.34M | 25.33M | 46.24M | 46.00M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 10.26M | -1.07M | -29.83M | -17.45M | 1.09M |